Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Trends in triple negative breast cancer in California over 15 years.

Sub-category:
Adjuvant Therapy

Category:
Breast Cancer—Local/Regional/Adjuvant

Meeting:
2018 ASCO Annual Meeting

Abstract No:
e12569

Citation:
J Clin Oncol 36, 2018 (suppl; abstr e12569)

Author(s): Carol Parise, Vincent Caggiano; Sutter Institute for Medical Research, Sacramento, CA

Abstract Disclosures

Abstract:

Background: ER+/PR+/HER2- is the most common subtype and has the best survival and triple negative breast cancer (TNBC) is the second most common subtype and has the worst survival. The purpose of this study was to assess trends in diagnosis of TNBC versus ER+/PR+/HER2- over 15 years. Methods: We identified 221,205 cases of first primary female invasive breast cancer from the California Cancer Registry 2000-2014. 130,758 (59.7%) were ER+/PR+/HER2-, 27,278 (12.3%) were TNBC and the remaining 63,169 (28.6%) were the six remaining subtypes. The ratio of ER+/PR+/HER2- to TNBC cases diagnosed per year was computed. Results: The number of cases of both subtypes increased over time. TNBC was diagnosed at a higher percentage in 2000-2009 than it was in 2010-2014. The opposite was true for ER+/PR+/HER2- (Table 1). The ratio of diagnoses of ER+/PR+/HER2- to TNBC increased 48% over the 15 year period. Conclusions: The number of cases of ER+/PR+/HER2-, the subtype with the best survival continues to increase over time while the incidence of TNBC, the subtype with the worst survival, appears to have stabilized.

YearN% of ER+/PR+/
HER2-
% of ER+/PR+/
HER2-/year
N% of TNBC% of TNBC/yearRatioTotal
2,0004,8873.7%80.5%1,1874.4%19.5%4.126,074
2,0015,8554.5%81.2%1,3595.0%18.8%4.317,214
2,0025,8954.5%81.2%1,3665.0%18.8%4.327,261
2,0036,4915.0%79.7%1,6566.1%20.3%3.928,147
2,0046,2944.8%78.9%1,6826.2%21.1%3.747,976
2,0056,9005.3%80.1%1,7176.3%19.9%4.028,617
2,0068,1126.2%80.5%1,9687.2%19.5%4.1210,080
2,0079,1477.0%82.2%1,9777.2%17.8%4.6311,124
2,0089,6807.4%81.6%2,1778.0%18.4%4.4511,857
2,0099,8257.5%82.3%2,1137.7%17.7%4.6511,938
2,01010,3067.9%83.6%2,0197.4%16.4%5.1012,325
2,01111,3208.7%84.7%2,0417.5%15.3%5.5513,361
2,01211,7799.0%85.5%2,0047.3%14.5%5.8813,783
2,01312,1759.3%85.7%2,0377.5%14.3%5.9814,212
2,01412,0929.2%86.0%1,9757.2%14.0%6.1214,067
Total130,75827,278158,036

 
Other Abstracts in this Sub-Category:

 

1. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.

Meeting: 2018 ASCO Annual Meeting Abstract No: LBA1 First Author: Joseph A. Sparano
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

2. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.

Meeting: 2018 ASCO Annual Meeting Abstract No: 500 First Author: Michael Gnant
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

3. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.

Meeting: 2018 ASCO Annual Meeting Abstract No: 501 First Author: Robert E. Coleman
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

More...